Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
IDEXX LABORATORIES INC /DE
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-74.0% vs price
Base Case (Median)
-64.1% vs price
Bull Case (75th pct.)
-39.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $155.10 | -70.1% | High (40%) |
| PE Comparable | $319.53 | -38.4% | Medium (25%) |
| Growth Trajectory DCF | $363.10 | -30.0% | Medium (20%) |
| Graham Number | $80.69 | -84.4% | Medium (40%) |
| EV/EBITDA | $185.98 | -64.1% | Medium (20%) |
| EV/FCF | $312.70 | -39.7% | Medium (20%) |
| Earnings Power Value | $114.53 | -77.9% | Medium (50%) |
Based on 7 out of 7 methods, IDXX appears overvalued at the current price of $518.39. The base case fair value of $185.98 implies 64.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.